View presentation - Institute for e

Syndromic Surveillance
Meaningful Use Recommendations
November 16, 2011
Taha A. Kass-Hout, MD, MS
Deputy Director for Information Science and BioSense Program Manager
Division of Notifiable Diseases and Healthcare Information (DNDHI, Proposed)
Public Health Surveillance Program Office (PHSPO)
Office of Surveillance, Epidemiology, and Laboratory Services (OSELS)
Centers for Disease Control & Prevention (CDC)
Any views or opinions expressed here do not necessarily represent the views of the CDC, HHS, or any other entity of the United States
government. Furthermore, the use of any product names, trade names, images, or commercial sources is for identification purposes only,
and does not imply endorsement or government sanction by the U.S. Department of Health and Human Services.
Office of Surveillance, Epidemiology, and Laboratory Services
Public Health Surveillance Program Office
Background
CDC AND ISDS MEANINGFUL USE
RECOMMENDATIONS
CMS EHR Incentive Programs
“Meaningful Use”
Stage 2
Advanced
clinical
Stage 1
processes
Data capture (2013-2014)
and sharing
(2011-2012)
Stage 3
Improved
outcomes
(2015-2016)
Meaningful Use Rules in July 2010
?
?
?
Development Process
THE RECOMMENDATION
CDC and ISDS Recommendation

Responded to needs for





Clarity in the MUse rule for Syndromic Surveillance
Support PHA’s participation in MUse
Contemporary picture of practice
A minimum (core and optional) standard
Is based on
 Best practices
 Core business needs

Establishes a foundation











Michael A. Coletta, MPH (Workgroup Chair), Virginia Department of Health
Ryan Gentry, Indiana State Department of Health
Julia E. Gunn, RN, MPH, Boston Public Health Commission
Richard S. Hopkins, MD, MSPH, Florida Department of Health
Amy Ising, MSIS, University of North Carolina Department of Emergency Medicine at
Chapel Hill
Geraldine S. Johnson, MS, New York State Department of Health
Bryant T. Karras, MD, State of Washington, Department of Health
Karl Soetebier, Georgia Department of Community Health
David Swenson, MEd, State of New Hampshire, Department of Public Health Services
David Buckeridge, MD, PhD, McGill University and Montreal Public Health
Office of Surveillance, Epidemiology, and Laboratory Science and Career Development,
CDC
 Public Health Surveillance Program Office
 Partnerships and Planning Activity: Pamela A. Meyer, PhD, MSPH
 Division of Healthcare Information: Samuel Groseclose, DVM, MPH; Taha
Kass-Hout, MD, MS
 Public Health Informatics and Technology Program Office:
 Standards and Inoperability: Nikolay Lipskiy, MD, DrPH, MBA
 Northrop Grumman: Sergei Li, PMP; Sundak Ganesan, MD; Mark Meadows;
Adam Browning; Mary Hamilton
AHIC Biosurveillance MDS
NHIN Biosurveillance UC
HITSP Biosurveillance
Interoperability Specification
[20081218 V3.2]
Current SS Landscape
•Distribute
[40 jurisdictions]
•BioSense
[28 jurisdictions]
Draft Minimum
Data Set
Consensus-driven Development
1. ISDS MU Workgroup informed early iterations. SME’s included
representation from CSTE, and NACCHO
2. Stakeholder input help validate, refine and better contextualized the
recommendations
3. 41 stakeholders commented; ~ 20% corporations or professional
organizations
•
4 EP’s or Hospital
•
9 Vendors
•
20 Public Health
•
2 Other
Contents
THE RECOMMENDATION
Scope
Data Source: Data on emergency
department (ED) and urgent care
(UC) patient visits captured by
health information system and sent
to a public health authority defines
the scope of this recommendation.
Surveillance Goal: Assessment of
community and population health
for all-hazards defines the scope of
this recommendation.
Message and Vocabulary
Standards: Standards that support
current and continued PHSS
improvements, while maintaining
consistency with those standards
required by the CMS EHR
Reimbursement Program define the
scope of this recommendation
Meaningful Use Rules in July 2010
?
?
?
Meaningful Use Rules in October 2011
33 Elements
17 Core
16 Optional
3 Core Business Processes
Performing
Syndrome-based
Surveillance
Establishing
New Data
Source
Monitoring
Data
Quality
NOW AVAILABLE
PHIN Guide for SS : ED & UC Data, Release 1.0
Revised and improved
• Based on feedback through Federal Registry post 5/11-6/11
• Better suit the intent of Meaningful Use policy
• Added FAQ to address specific issues and needs for
clarification
Highlight changes
• Data Elements of Interest – Usage
• 17 required (R or RE)
• 16 optional (O)
• Data Elements of Interest – Vocabulary
• Treatment Facility ID
• Race, Ethnicity, Gender
• Extended data elements
• Increased guidance
• Business rules
• Transmission and updating
http://www.cdc.gov/EHRmeaningfuluse/Syndromic.html
Continuing work on
PHSS Meaningful Use
Develop business and
infrastructure requirements
for syndromic surveillance
using
• Inpatient care data
• Ambulatory care data
(EP’s)
✔
Thank You!
Taha A. Kass-Hout, MD, MS
Deputy Director for Information Science and BioSense Program Manager
Division of Notifiable Diseases and Healthcare Information (DNDHI, Proposed)
Public Health Surveillance Program Office (PHSPO)
Office of Surveillance, Epidemiology, and Laboratory Services (OSELS)
Centers for Disease Control & Prevention (CDC)
Any views or opinions expressed here do not necessarily represent the views of the CDC, HHS, or any other entity of the United States
government. Furthermore, the use of any product names, trade names, images, or commercial sources is for identification purposes only,
and does not imply endorsement or government sanction by the U.S. Department of Health and Human Services.